[1025] Hormonotherapy in Prostate Cancer Influences Tumor Microvessel Density: New Perspectives for Prostate Cancer Treatment?

Raffaella Santi, Eva Comperat, Lorenzo Masieri, Sergio Serni, Philippe Camparo, Marco Carini, Gabriella Nesi. University of Florence, Florence, Italy; Hopital La Pitié Salpetrière, Paris, France; Centre de Pathologie Amiens Picardie, Amiens, France

Background: Radical prostatectomy (RP) represents an effective option for prostate cancer (PCa) treatment. In selected cases, surgery may follow neoadjuvant hormonotherapy. It has been proven that angiogenesis plays a crucial role in PCa growth. The aim of this study was to investigate the effects of hormonotherapy on Microvessel Density (MVD) and pathologic stage in a series of PCa patients treated with RP.
Design: Ninety-six RP cases were retrospectively collected. Fifty-one patients had surgery only (untreated) while 45 received androgen ablation therapy (treated) for 3 months before surgery. Tissue microarrays (TMAs) were constructed using 3 tissue cores for each tumor sample. Endothelial expression of CD31 (DAKO, Denmark) and LYVE-1 (Santa Cruz, CA) was assessed immunohistochemically. CD31 and LYVE-1 staining hot spot areas were used to evaluate MVD with a semi-quantitative scoring system.
Results: Median age of patients was 65.3 years (range: 49-75 years). Pathologic stage was T2 in 24 untreated and 28 treated patients and T3 in 21 untreated and 23 treated patients. Hormonotherapy was significantly associated with increased MVD measured by CD31 (p=0.009) and LYVE-1 (p<0.001) expression. In addition, a statistically significant correlation was demonstrated between high pathologic stage and increased MVD obtained by CD31 (p=0.026) but not by LYVE-1 staining.
Conclusions: Our study showed a correlation between hormonotherapy and increase in the number of intra-tumoral vessels, particularly the lymphatic ones. Although the mechanism by which hormonotherapy increases MVD in PCa remains to be elucidated, anti-angiogenic therapy should be considered in PCa patients undergoing total androgen ablation.
Category: Genitourinary (including renal tumors)

Wednesday, March 6, 2013 9:30 AM

Poster Session V # 130, Wednesday Morning


Close Window